This is to inform you that the Board of Directors of the Company has at its meeting held today, recommended payment of Final Dividend for the Financial Year 2024-25 of Rs. 5/- (250%) per equity share of Rs. 2 each, subject to the approval of shareholders at the ensuing Annual General Meeting.

pdf

Alivus Life Sciences Ltd.

15 May 2025

1014.60

-0.74%

Board Meeting

Alivus Life Sciences Ltd - 543322 - Board Meeting Outcome for Audited Financial Results For The …

BSE India

Audited Financial Results for the Fourth Quarter and Year ended March 31, 2025

pdf

Alivus Life Sciences Ltd.

15 May 2025

1014.60

-0.74%

Result

Alivus Life Sciences Ltd - 543322 - Audited Financial Results For The Fourth Quarter And Year …

BSE India

Please find enclosed herewith Audited Financial Results for the Fourth Quarter and Year Ended March 31, 2025

pdf

Alivus Life Sciences Ltd.

08 May 2025

1014.60

-0.74%

Company Update

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Enclosed please find herewith the details of Earnings Call slated for Friday, May 16, 2025 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record.

pdf

Alivus Life Sciences Ltd.

08 May 2025

1014.60

-0.74%

SAST

Alivus Life Sciences Ltd - 543322 - Closure of Trading Window

BSE India

As per the ''Code of Conduct for Prevention of Insider Trading" and pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ''designated persons'' regarding closure of Trading Window from March 31, 2025 to May 17, 2025 (both days inclusive) for the purpose of approval of Audited Financial Results for quarter and year ended March 31, 2025

pdf

Alivus Life Sciences Ltd.

08 May 2025

1014.60

-0.74%

Board Meeting

Alivus Life Sciences Ltd - 543322 - Board Meeting Intimation for To Consider And Approve The …

BSE India

Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 ,inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended 31st March, 2025 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2025.

pdf